Company

Novartis

Official Name: Novartis AG

Headquarters: Basel, Switzerland

Founded: March 1996

Employees: 104,323

SIX: NOVN -1.27%

Market Cap

CHF185.40 Billion

CHF as of Jan. 1, 2024

US$220.27 Billion

history Market Cap History

Company Description

Novartis AG is a global healthcare company that researches, develops, manufactures, and markets healthcare products. It operates through two segments: Innovative Medicines, offering prescription drugs across various therapeutic areas, and Sandoz, which develops, manufactures, and markets finished dosage form medicines, and provides active pharmaceutical ingredients, biosimilars, and biotechnology manufacturing services. Novartis collaborates with various entities to enhance its product offerings.

Novartis market capitalization over time

Evolution of Novartis AG market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Novartis AG

Detailed Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

🐷

"Bulls make money...
Bears make money...
Pigs get slaughtered!"

Stop guessing, unlock Financial AI.

(Don't be a pig.)

Product & Services

Pharmaceutical Research and Development, Pharmaceutical Manufacturing, Prescription Medicines, Ophthalmology, Neuroscience, Immunology, Hepatology, Dermatology, Respiratory Medicine, Cardiovascular Medicine, Renal and Metabolism Medicine, Generics, Biosimilars, Biotechnology Manufacturing Services

Key People

Founder(s): Johann Rudolf Alexander Clavel

Vasant Narasimhan (CEO)

Financials

Revenue: US$49.89 billion (2020)

Operating income: US$10.15 billion (2020)

Net income: US$8.07 billion (2020)


Total assets: US$132.06 billion (2020)

Total equity: US$56.67 billion (2020)

Details

Headquarters:

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 1111

Fax: 41 61 324 8001